Chemical Information
Antiviral agent ID	DrugRepV_2153
Antiviral agent name	BCX4430 Dihydrochloride
IUPAC Name	(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol;dihydrochloride
SMILES (canonical)	C1=C(C2=C(N1)C(=NC=N2)N)C3C(C(C(N3)CO)O)O.Cl.Cl
SMILES (isomeric)	C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl.Cl
Molecular Formula	C11H17Cl2N5O3
Molecular Weight (g/mol)	338.189
InChl	InChI=1S/C11H15N5O3.2ClH/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7;;/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15);2*1H/t5-,7+,9-,10+;;/m1../s1
Structural Information
Clinical Information
Primary Indication (Clinical trial phases)	Phase I
Biological Information
Primary Indication (Disease Category)	Infectious Disease
Primary Indication (Disease)	Ebola virus
Secondary Indication	Zika virus (ZIKV) NA Ugandan MR-766
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	in-vivo
Secondary Indication (Model system) [cell lines/ animal models]	Huh-7
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	6.4 μM
Secondary Indication (Cell based assay)	Virus yield reduction assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC90 [ 90 % ]
Reference	Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, Stewart J, Collins P, Gebre M, Ne.Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in.Antiviral Res. 2017 Jan;137:14-22. doi: 10.1016/j.antiviral.2016.11.003. Epub 2016 Nov 10. PMID:27838352
Comment	Treatment of ZIKV-infected mice with BCX4430 significantly improved outcome even when treatment was initiated during the peak of viremia. The demonstration of potent activity of BCX4430 against ZIKV in a lethal mouse model warrant its continued clinical development.